Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $294.06 +2.04%
EPS Growth %: +409.4%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +409.4%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.62), $0.10 worse than the analyst estimate of ($1.52). Revenue for the quarter came in at $305.7 million versus the consensus estimate of $332.83 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- Qualcomm targets $40B in non-handset revenue by fiscal 2029
- Paychex beats fourth quarter EPS estimates, stock slides
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
